Lotus Eye Hospital decides against voluntary delisting; shares to remain on NSE & BSELotus Eye Hospital decides against voluntary delisting; shares to remain on NSE & BSE

Introduction

Leading healthcare provider decided against voluntary delisting from NSE and will continue listing on both NSE and BSE to maintain market presence and investor accessibility.

Also Read: Sun Pharma stock inches up after getting US FDA nod to review ILUMYA for new arthritis use

Share price movement of Lotus Eye Hospital

On March 18, 2026, Lotus Eye Hospital and Institute Ltd opened at ₹107.25, up 0.80% from its previous close of ₹106.40. The stock reached a high of ₹109.00 (2.44%) and a low of ₹105.40. By 4:00 PM, it traded at ₹106.90, a 0.47% increase, with a market cap of ₹226.68 crore. 

Lotus Eye Cancels NSE Delisting

Lotus Eye Hospital and Institute Limited’s Board decided not to pursue voluntary delisting of its equity shares from NSE. The decision considers market conditions, liquidity, and investor convenience.

The company will remain listed on both BSE and NSE. The Board meeting was held on March 17, 2026, from 4:30 PM to 5:00 PM, approving continuation of stock exchange listings.

Stock performance of Lotus Eye Hospital for period of 1 week, 6 months, and 1 year

Lotus Eye Hospital and Institute Ltd delivered a 1-week return of -2.75%, a 6-month return of -12.0%, and a 1-year return of 86.3%.

Also Read: Reliance Industries shares move up after securing long-term green ammonia offtake agreement with Samsung C&T, details here

Shareholding pattern of Lotus Eye Hospital

Particulars	Dec 2025	Sep 2025	Jun 2025
Promoter	40.70%	40.60%	40.40%
FII	0.00%	0%	0.00%
DII	0.00%	0.00%	0.00%
Public	59.30%	59.30%	59.60%

About Lotus Eye Hospital

Lotus Eye Hospital and Institute Ltd (NSE: LOTUSEYE) is a listed corporate eye hospital offering ophthalmology and related services across 8 centers in Tamil Nadu and Kerala.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs